MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130.7 USD | +2.93% |
|
+4.38% | +19.90% |
Financials (USD)
| Sales 2024 * | 63.7B | Sales 2025 * | 68.24B | Capitalization | 322B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.09B | Net income 2025 * | 21.78B | EV / Sales 2024 * | 5.36 x |
| Net Debt 2024 * | 19.65B | Net Debt 2025 * | 7.53B | EV / Sales 2025 * | 4.82 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
14.3
x | Employees | 71,000 |
| Yield 2024 * |
2.41% | Yield 2025 * |
2.55% | Free-Float | 70.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 day | +2.94% | ||
| 1 week | +4.38% | ||
| Current month | -0.93% | ||
| 1 month | +4.32% | ||
| 3 months | +8.82% | ||
| 6 months | +26.14% | ||
| Current year | +19.90% |
1 week
124.89
132.80
1 month
124.50133.10
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 215 M€ | +12.27% | - | |
| 5.61% | 18 M€ | +3.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 130.7 | +2.93% | 12 739 820 |
| 24-04-24 | 127 | +0.09% | 7,128,300 |
| 24-04-23 | 126.9 | -0.05% | 7,743,961 |
| 24-04-22 | 126.9 | +0.92% | 7,805,992 |
| 24-04-19 | 125.8 | +0.44% | 8,404,345 |
Delayed Quote Nyse, April 25, 2024 at 04:02 pm EDT
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
06:30am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
127
USD
Average target price
137.6
USD
Spread / Average Target
+8.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.90% | 322B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B | |
| +2.07% | 117B |
- Stock Market
- Equities
- MRK Stock
